John Goldberg, MD
Internal Medicine · Overland Park, KSNPI 1154349322
Payments from drug & device makers
Across 209 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$546
- AbbVie$489
- Lilly USA, LLC$409
- AstraZeneca$393
- Pfizer$284
- Amgen$244
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,787100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $546 |
| AbbVie | 27 | $489 |
| Lilly USA, LLC | 22 | $409 |
| AstraZeneca(2 entities) | 21 | $393 |
| Pfizer | 17 | $284 |
| Amgen | 13 | $244 |
| Bayer | 6 | $102 |
| Johnson & Johnson | 5 | $100 |
| Astellas Pharma US Inc | 5 | $95 |
| Merck | 6 | $90 |
| Exact Sciences | 6 | $88 |
| Boehringer Ingelheim | 4 | $81 |
| Alnylam Pharmaceuticals Inc. | 4 | $75 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Idorsia Pharmaceuticals US Inc | 3 | $63 |
| Radius Health, Inc. | 2 | $62 |
| Ipsen Biopharmaceuticals, Inc | 2 | $55 |
| Kyowa Kirin, Inc. | 2 | $46 |
| Dexcom, Inc. | 1 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| GSK | 3 | $41 |
| Lifescan, Inc. | 2 | $37 |
| Sandoz | 1 | $33 |
| Mannkind Corporation | 2 | $33 |
| Cequr Corporation | 1 | $29 |
| Amarin Pharma, Inc. | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
How this compares
$3,787 in reported general payments places this provider in the 85th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $122,888 |
| JardianceEmpagliflozin | 118 | $120,416 |
| EliquisApixaban | 101 | $113,442 |
| TrulicityDulaglutide | 36 | $60,140 |
| JanuviaSitagliptin Phosphate | 51 | $57,737 |
| XareltoRivaroxaban | 37 | $42,235 |
| RybelsusSemaglutide | 20 | $35,612 |
| MounjaroTirzepatide | 25 | $31,510 |
| MyrbetriqMirabegron | 42 | $30,075 |
| FarxigaDapagliflozin Propanediol | 25 | $26,291 |
| LinzessLinaclotide | 30 | $16,795 |
| TradjentaLinagliptin | 17 | $15,583 |
| Praluent PenAlirocumab | 25 | $12,573 |
| Repatha SureclickEvolocumab | 13 | $10,483 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $546 | $158,501125 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $81 | $143,601150 claims |
| PfizerEliquis | $284 | $113,442101 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $409 | $91,65061 claims |
| MerckJanuvia | $90 | $57,73751 claims |
| Johnson & JohnsonXarelto | $100 | $42,23537 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $30,07542 claims |
| AstraZenecaFarxiga, Symbicort | $393 | $28,77536 claims |
| AbbVieLinzess, Synthroid | $489 | $18,54054 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $3,795431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Overland Park
- Jonathan JacobsOverland Park$827K
- Thomas CuevasOverland Park$382K
- Lisa VansaghiOverland Park$131K
- Herbert WaxmanOverland Park$82K
- Shadrach SmithOverland Park$27K
- David EdalatiOverland Park$21K
- Jennifer BrownOverland Park$9K
- Ammar KhalifaOverland Park$8K
- Bruce SalvaggioOverland Park$8K
- Vijaya SamuelOverland Park$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.